Pyxis Oncology, Inc. (PYXS)
$3.54
+0.03
(+0.85%)▲
Market is closed - opens 7 PM, 07 Oct 2024
Performance
- $3.48$3.65$3.54
1.69%
Downside
Day's Volatility :4.66%
Upside
3.01%
- $1.35$6.85$3.54
61.86%
Downside
52 Weeks Volatility :80.29%
Upside
48.32%
Returns
| Period | Pyxis Oncology, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 22.3% | 4.9% | 0.0% |
6 Months | -37.1% | 5.8% | 0.0% |
1 Year | 67.94% | 16.5% | 0.0% |
3 Years | -73.41% | 20.3% | -20.1% |
Highlights
Market Capitalization | 208.6M |
Book Value | $2.88 |
Earnings Per Share (EPS) | -1.27 |
Wall Street Target Price | 9.17 |
Profit Margin | 0.0% |
Operating Margin TTM | -409.25% |
Return On Assets TTM | -21.53% |
Return On Equity TTM | -37.58% |
Revenue TTM | 16.1M |
Revenue Per Share TTM | 0.33 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -63.2M |
Diluted Eps TTM | -1.27 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.04 |
EPS Estimate Next Year | -1.17 |
EPS Estimate Current Quarter | -0.32 |
EPS Estimate Next Quarter | -0.3 |
Analyst Recommendation
Buy
92%Buy
7%Hold
0
0%Sell
Based on 13 Wall street analysts offering stock ratings for Pyxis Oncology, Inc.(by analysts ranked 0 to 5 stars)
Based on 13 analyst
- Current
- 1M Ago
- 3M Ago
Buy
12
12
11
Hold
1
1
1
Sell
00
00
00
Analyst Forecast
What analysts predicted
Upside of 159.04%
Current $3.54
Target $9.17
Technicals Summary
Sell
Neutral
Buy
Pyxis Oncology, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Pyxis Oncology, Inc. | 0.29% | -37.1% | 67.94% | -73.41% | -73.41% |
 Regeneron Pharmaceuticals, Inc. | -10.33% | 8.11% | 21.28% | 85.63% | 257.49% |
 Novo Nordisk A/s | -12.25% | -9.71% | 24.92% | 138.38% | 343.21% |
 Alnylam Pharmaceuticals, Inc. | 9.22% | 72.73% | 52.35% | 34.04% | 250.13% |
 Vertex Pharmaceuticals Incorporated | -3.09% | 12.2% | 25.77% | 150.7% | 163.62% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Pyxis Oncology, Inc. | NA | NA | NA | -1.04 | -0.38 | -0.22 | NA | 2.88 |
Regeneron Pharmaceuticals, Inc. | 27.55 | 27.55 | 1.42 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.7 | 38.7 | 1.75 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.55 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Pyxis Oncology, Inc. | Buy | $208.6M | -73.41% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $114.7B | 257.49% | 27.55 | 32.04% |
Novo Nordisk A/s | Buy | $518.0B | 343.21% | 38.7 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.9B | 250.13% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $119.3B | 163.62% | 32.84 | -4.74% |
Institutional Holdings
Deep Track Capital, LP
7.10%LAURION CAPITAL MANAGEMENT LP
6.55%BlackRock Inc
4.73%Balyasny Asset Management LLC
4.35%Vanguard Group Inc
3.50%Ikarian Capital, LLC
2.82%
Company Information
pyxis oncology is developing antibody therapeutics to promote the body's immune response to cancer, based on new insights into the tumor micro-environment.
Organization | Pyxis Oncology, Inc. |
Employees | 55 |
CEO | Dr. Lara S. Sullivan M.D., MBA |
Industry | Services |
